Skip to main content

Amgen income statement

  • AMGN · Nasdaq
  • Biotechnology
  • S&P 500
$465.67−0.30%Close 13 Nov 2026 · Market value $253.3B

Amgen reported revenue of $36.8 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 10.0% from fiscal 2024. Net income was $7.71 billion and diluted earnings per share $14.23.

From Amgen's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Amgen income statement, annual
USDFY 2007FY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Revenue$14.77B$15.00B$14.64B$15.05B$15.58B$17.27B$18.68B$20.06B$21.66B$22.99B$22.85B$23.75B$23.36B$25.42B$25.98B$26.32B$28.19B$33.42B$36.75B$38.90B
Revenue growth—+1.6%−2.4%+2.8%+3.5%+10.8%+8.2%+7.4%+8.0%+6.1%−0.6%+3.9%−1.6%+8.8%+2.2%+1.3%+7.1%+18.6%+10.0%—
Cost of revenue————$2.71B$3.20B$3.35B$4.42B$4.23B$4.16B$4.07B$4.10B$4.36B$6.16B$6.45B$6.41B$8.45B$12.86B$12.04B$11.32B
Gross profit————$12.87B$14.07B$15.33B$15.64B$17.43B$18.83B$18.78B$19.65B$19.01B$19.27B$19.52B$19.92B$19.74B$20.57B$24.71B$27.58B
Gross margin————82.6%81.5%82.1%78.0%80.5%81.9%82.2%82.7%81.4%75.8%75.2%75.7%70.0%61.5%67.2%70.9%
Selling, general and administrative$3.36B$3.79B$3.82B$3.98B$4.50B$4.81B$5.18B$4.70B$4.85B$5.06B$4.87B$5.33B$5.15B$5.73B$5.37B$5.41B$6.18B$7.10B$7.05B$6.98B
Operating income$3.98B$5.21B$5.51B$5.54B$4.31B$5.58B$5.87B$6.19B$8.47B$9.79B$9.97B$10.26B$9.67B$9.14B$7.64B$9.57B$7.90B$7.26B$9.08B$12.61B
Operating margin26.9%34.8%37.6%36.8%27.7%32.3%31.4%30.9%39.1%42.6%43.6%43.2%41.4%35.9%29.4%36.3%28.0%21.7%24.7%32.4%
Interest expense$496.0M$551.0M$578.0M$604.0M$610.0M$1.05B$1.02B$1.07B$1.09B$1.26B$1.30B$1.39B$1.29B$1.26B$1.20B$1.41B$2.88B$3.15B$2.75B$2.64B
Other income and expense$309.0M$352.0M$276.0M$376.0M$448.0M$485.0M$420.0M$465.0M$603.0M$629.0M$928.0M$674.0M$753.0M$256.0M$259.0M−$814.0M$2.83B$506.0M$2.65B$1.08B
Income before tax$3.79B$5.01B$5.20B$5.32B$4.15B$5.01B$5.26B$5.58B$7.98B$9.16B$9.60B$9.54B$9.14B$8.13B$6.70B$7.35B$7.86B$4.61B$8.98B$11.05B
Income tax expense$715.0M$963.0M$599.0M$690.0M$467.0M$664.0M$184.0M$427.0M$1.04B$1.44B$7.62B$1.15B$1.30B$869.0M$808.0M$794.0M$1.14B$519.0M$1.26B$1.66B
Effective tax rate18.9%19.2%11.5%13.0%11.3%13.3%3.5%7.6%13.0%15.7%79.4%12.1%14.2%10.7%12.1%10.8%14.5%11.3%14.1%15.0%
Net income$3.08B$4.05B$4.61B$4.63B$3.68B$4.34B$5.08B$5.16B$6.94B$7.72B$1.98B$8.39B$7.84B$7.26B$5.89B$6.55B$6.72B$4.09B$7.71B$9.39B
Net margin20.8%27.0%31.5%30.7%23.6%25.2%27.2%25.7%32.0%33.6%8.7%35.3%33.6%28.6%22.7%24.9%23.8%12.2%21.0%24.1%
EPS · diluted$2.74$3.77$4.51$4.79$4.04$5.52$6.64$6.70$9.06$10.24$2.69$12.62$12.88$12.31$10.28$12.11$12.49$7.56$14.23$17.26
Diluted weighted average shares1.1B1.1B1.0B965M912M787M765M770M766M754M735M665M609M590M573M541M538M541M542M544M
Basic weighted average shares1.1B1.1B1.0B960M905M775M753M759M758M748M731M661M605M586M570M538M535M537M538M540M
EBITDA$5.18B$6.29B$6.55B$6.56B$5.37B$6.67B$7.15B$8.28B$10.58B$11.90B$11.93B$12.21B$11.88B$12.74B$11.04B$12.98B$11.97B$12.85B$14.25B$17.09B
EBITDA margin35.1%41.9%44.8%43.6%34.5%38.6%38.3%41.3%48.8%51.8%52.2%51.4%50.9%50.1%42.5%49.3%42.5%38.4%38.8%43.9%
Depreciation & amortization$1.20B$1.07B$1.05B$1.02B$1.06B$1.09B$1.29B$2.09B$2.11B$2.10B$1.96B$1.95B$2.21B$3.60B$3.40B$3.42B$4.07B$5.59B$5.17B$4.48B
Stock-based compensation$263.0M$262.0M$284.0M$353.0M$341.0M$362.0M$403.0M$408.0M$322.0M$311.0M$329.0M$311.0M$308.0M$330.0M$341.0M$401.0M$431.0M$530.0M$494.0M$493.0M
Dividends per share—————————$4.15$4.77$5.41$5.95$6.56$7.22$7.95$8.64$9.13$9.66$10.08

Quarterly

Amgen income statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$8.20B$7.45B$8.39B$8.50B$9.09B$8.15B$9.18B$9.56B$9.87B$8.62B$10.05B$10.37B
Cost of revenue$3.11B$3.20B$3.24B$3.31B$3.11B$2.97B$3.01B$3.08B$2.98B$2.74B$2.81B$2.79B
Gross profit$5.08B$4.25B$5.15B$5.19B$5.97B$5.18B$6.17B$6.47B$6.89B$5.87B$7.24B$7.58B
Gross margin62.0%57.0%61.4%61.1%65.7%63.6%67.2%67.8%69.8%68.2%72.0%73.1%
Selling, general and administrative$2.27B$1.81B$1.78B$1.63B$1.88B$1.69B$1.69B$1.72B$1.95B$1.60B$1.75B$1.68B
Operating income$1.27B$991.0M$1.91B$2.05B$2.31B$1.18B$2.66B$2.53B$2.72B$2.67B$3.51B$3.71B
Operating margin15.5%13.3%22.8%24.1%25.4%14.5%28.9%26.4%27.6%30.9%35.0%35.8%
Interest expense$821.0M$824.0M$808.0M$776.0M$747.0M$723.0M$694.0M$685.0M$653.0M$657.0M$673.0M$653.0M
Other income and expense$402.0M−$235.0M−$307.0M$1.83B−$782.0M$1.52B−$394.0M$2.08B−$553.0M$75.00M−$73.00M$1.63B
Income before tax$852.0M−$68.00M$794.0M$3.10B$782.0M$1.97B$1.57B$3.92B$1.51B$2.08B$2.77B$4.69B
Income tax expense$85.00M$45.00M$48.00M$271.0M$155.0M$243.0M$136.0M$705.0M$181.0M$265.0M$393.0M$822.0M
Effective tax rate10.0%−66.2%6.0%8.7%19.8%12.3%8.7%18.0%12.0%12.7%14.2%17.5%
Net income$767.0M−$113.0M$746.0M$2.83B$627.0M$1.73B$1.43B$3.22B$1.33B$1.82B$2.38B$3.86B
Net margin9.4%−1.5%8.9%33.3%6.9%21.2%15.6%33.7%13.5%21.1%23.6%37.3%
EPS · diluted$1.43−$0.21$1.38$5.22$1.16$3.20$2.65$5.93$2.46$3.34$4.37$7.08
Diluted weighted average shares537M536M541M542M541M541M541M542M542M544M544M546M
Basic weighted average shares535M536M537M537M537M538M538M538M538M540M540M541M
EBITDA$2.65B$2.39B$3.31B$3.44B$3.71B$2.56B$3.98B$3.86B$3.85B$3.78B$4.63B$4.83B
EBITDA margin32.3%32.1%39.5%40.5%40.8%31.5%43.3%40.4%39.0%43.9%46.0%46.6%
Depreciation & amortization$1.38B$1.40B$1.40B$1.40B$1.40B$1.39B$1.32B$1.33B$1.13B$1.12B$1.11B$1.12B
Stock-based compensation$161.0M$103.0M$157.0M$136.0M$134.0M$85.00M$157.0M$127.0M$125.0M$75.00M$165.0M$128.0M
Dividends per share$2.13$2.25$0.00$2.25$2.25$2.38$0.00$2.38$2.52$2.52$2.52$2.52

The main figures as JSON and plain text. See data and methodology.

AMGN in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.